IN2014DN01619A - - Google Patents
Info
- Publication number
- IN2014DN01619A IN2014DN01619A IN1619DEN2014A IN2014DN01619A IN 2014DN01619 A IN2014DN01619 A IN 2014DN01619A IN 1619DEN2014 A IN1619DEN2014 A IN 1619DEN2014A IN 2014DN01619 A IN2014DN01619 A IN 2014DN01619A
- Authority
- IN
- India
- Prior art keywords
- relates
- present
- bisbenzonitrile
- triazol
- medicaments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to low dose pharmaceutical compositions comprising the aromatase inhibitor 4 4 [fluoro (1 H 1 2 4 triazol 1 yl)methylene]bisbenzonitrile as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532459P | 2011-09-08 | 2011-09-08 | |
| US201261638588P | 2012-04-26 | 2012-04-26 | |
| PCT/US2012/053846 WO2013036563A1 (en) | 2011-09-08 | 2012-09-06 | Pharmaceutical compositions comprising an aromatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN01619A true IN2014DN01619A (en) | 2015-05-15 |
Family
ID=46846026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1619DEN2014 IN2014DN01619A (en) | 2011-09-08 | 2012-09-06 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9295668B2 (en) |
| EP (2) | EP2753312B1 (en) |
| JP (2) | JP6051467B2 (en) |
| KR (3) | KR20140071358A (en) |
| CN (2) | CN103796644B (en) |
| AR (1) | AR087790A1 (en) |
| AU (2) | AU2012304693B2 (en) |
| BR (2) | BR112014004879B1 (en) |
| CA (2) | CA2846884C (en) |
| CL (1) | CL2014000552A1 (en) |
| CY (2) | CY1118461T1 (en) |
| DK (2) | DK2753313T3 (en) |
| ES (2) | ES2613666T3 (en) |
| HR (2) | HRP20170002T1 (en) |
| HU (2) | HUE031478T2 (en) |
| IL (1) | IL231234A (en) |
| IN (1) | IN2014DN01619A (en) |
| LT (2) | LT2753312T (en) |
| MX (2) | MX360315B (en) |
| PE (1) | PE20141584A1 (en) |
| PL (2) | PL2753313T3 (en) |
| PT (2) | PT2753312T (en) |
| RU (2) | RU2617510C2 (en) |
| SG (2) | SG2014012132A (en) |
| SI (2) | SI2753313T1 (en) |
| TN (1) | TN2014000059A1 (en) |
| TW (1) | TW201316987A (en) |
| UY (1) | UY34315A (en) |
| WO (2) | WO2013036563A1 (en) |
| ZA (1) | ZA201401040B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6051467B2 (en) * | 2011-09-08 | 2016-12-27 | メレオ バイオファーマ ２ リミテッド | Pharmaceutical composition comprising an aromatase inhibitor |
| US10324099B2 (en) * | 2014-03-26 | 2019-06-18 | The Regents Of The University Of California | Ultrasensitive androgen receptor bioassay |
| PL3166596T3 (en) * | 2014-07-07 | 2018-11-30 | Novartis Ag | Pharmaceutical dosage forms |
| GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
| WO2018165145A1 (en) * | 2017-03-08 | 2018-09-13 | Ariad Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine |
| USD894148S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| USD894149S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| JP7121999B2 (en) * | 2019-09-26 | 2022-08-19 | 学校法人九州文化学園 | Male hypogonadism therapeutic agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749713A (en) | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| TW210334B (en) * | 1990-12-12 | 1993-08-01 | Ciba Geigy Ag | |
| DE4435368A1 (en) * | 1994-09-22 | 1996-03-28 | Schering Ag | Use of aromatase inhibitors for the manufacture of a medicament for the treatment of a relative androgen deficiency in men |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| WO2002002113A1 (en) * | 2000-07-05 | 2002-01-10 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition |
| CA2444932A1 (en) * | 2001-04-17 | 2002-10-24 | Ares Trading S.A. | Aromatase inhibition to enhance assisted reproduction |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| EP1492515A1 (en) * | 2002-04-03 | 2005-01-05 | Jencap Research Ltd. | Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male |
| EP1937251A2 (en) | 2005-04-25 | 2008-07-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| JPWO2009066712A1 (en) * | 2007-11-21 | 2011-04-07 | クラシエ製薬株式会社 | Aromatase inhibitor |
| JP6051467B2 (en) * | 2011-09-08 | 2016-12-27 | メレオ バイオファーマ ２ リミテッド | Pharmaceutical composition comprising an aromatase inhibitor |
-
2012
- 2012-09-06 JP JP2014529833A patent/JP6051467B2/en active Active
- 2012-09-06 EP EP12758965.3A patent/EP2753312B1/en active Active
- 2012-09-06 DK DK12758966.1T patent/DK2753313T3/en active
- 2012-09-06 BR BR112014004879A patent/BR112014004879B1/en active IP Right Grant
- 2012-09-06 ES ES12758965.3T patent/ES2613666T3/en active Active
- 2012-09-06 PT PT127589653T patent/PT2753312T/en unknown
- 2012-09-06 IN IN1619DEN2014 patent/IN2014DN01619A/en unknown
- 2012-09-06 PE PE2014000325A patent/PE20141584A1/en not_active Application Discontinuation
- 2012-09-06 AU AU2012304693A patent/AU2012304693B2/en active Active
- 2012-09-06 BR BR112014005434-7A patent/BR112014005434B1/en active IP Right Grant
- 2012-09-06 EP EP12758966.1A patent/EP2753313B1/en active Active
- 2012-09-06 US US14/342,810 patent/US9295668B2/en active Active
- 2012-09-06 RU RU2014113575A patent/RU2617510C2/en active
- 2012-09-06 PL PL12758966T patent/PL2753313T3/en unknown
- 2012-09-06 JP JP2014529832A patent/JP6280501B2/en active Active
- 2012-09-06 LT LTEP12758965.3T patent/LT2753312T/en unknown
- 2012-09-06 KR KR1020147006170A patent/KR20140071358A/en not_active Application Discontinuation
- 2012-09-06 LT LTEP12758966.1T patent/LT2753313T/en unknown
- 2012-09-06 RU RU2014113334A patent/RU2628808C2/en active
- 2012-09-06 SI SI201230848A patent/SI2753313T1/en unknown
- 2012-09-06 CN CN201280043378.9A patent/CN103796644B/en active Active
- 2012-09-06 KR KR1020147006171A patent/KR101872561B1/en active IP Right Grant
- 2012-09-06 AR ARP120103283A patent/AR087790A1/en unknown
- 2012-09-06 PL PL12758965T patent/PL2753312T3/en unknown
- 2012-09-06 PT PT127589661T patent/PT2753313T/en unknown
- 2012-09-06 DK DK12758965.3T patent/DK2753312T3/en active
- 2012-09-06 AU AU2012304694A patent/AU2012304694B2/en active Active
- 2012-09-06 HU HUE12758965A patent/HUE031478T2/en unknown
- 2012-09-06 SG SG2014012132A patent/SG2014012132A/en unknown
- 2012-09-06 CA CA2846884A patent/CA2846884C/en active Active
- 2012-09-06 MX MX2014002780A patent/MX360315B/en active IP Right Grant
- 2012-09-06 SI SI201230850T patent/SI2753312T1/en unknown
- 2012-09-06 KR KR1020187007058A patent/KR20180030254A/en not_active IP Right Cessation
- 2012-09-06 MX MX2014002773A patent/MX343902B/en active IP Right Grant
- 2012-09-06 CN CN201280043614.7A patent/CN103781476B/en active Active
- 2012-09-06 HU HUE12758966A patent/HUE031435T2/en unknown
- 2012-09-06 CA CA2845929A patent/CA2845929C/en active Active
- 2012-09-06 WO PCT/US2012/053846 patent/WO2013036563A1/en active Application Filing
- 2012-09-06 ES ES12758966.1T patent/ES2613667T3/en active Active
- 2012-09-06 SG SG10201607503WA patent/SG10201607503WA/en unknown
- 2012-09-06 WO PCT/US2012/053844 patent/WO2013036562A1/en active Application Filing
- 2012-09-06 US US14/342,813 patent/US9370505B2/en active Active
- 2012-09-07 TW TW101132840A patent/TW201316987A/en unknown
- 2012-09-10 UY UY0001034315A patent/UY34315A/en not_active Application Discontinuation
-
2014
- 2014-02-10 TN TNP2014000059A patent/TN2014000059A1/en unknown
- 2014-02-11 ZA ZA2014/01040A patent/ZA201401040B/en unknown
- 2014-02-27 IL IL231234A patent/IL231234A/en active IP Right Grant
- 2014-03-07 CL CL2014000552A patent/CL2014000552A1/en unknown
-
2016
- 2016-02-22 US US15/050,394 patent/US9750724B2/en active Active
- 2016-05-27 US US15/167,867 patent/US10064844B2/en active Active
-
2017
- 2017-01-03 HR HRP20170002TT patent/HRP20170002T1/en unknown
- 2017-01-03 HR HRP20170003TT patent/HRP20170003T1/en unknown
- 2017-01-18 CY CY20171100074T patent/CY1118461T1/en unknown
- 2017-01-24 CY CY20171100100T patent/CY1118499T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN01619A (en) | ||
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| IL231226A (en) | Compounds and compositions as c-kit kinase inhibitors, pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating diseases | |
| MY160456A (en) | Benzodiazepine bromodomain inhibitor | |
| MX338515B (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors. | |
| MX2012012438A (en) | Pharmaceutical formulations comprising pioglitazone and linagliptin. | |
| EP2522653A4 (en) | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | |
| MX2012013703A (en) | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors. | |
| WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
| MX2013001677A (en) | Stable formulations of linaclotide. | |
| TN2012000371A1 (en) | Pyrazole compounds as crth2 antagonists | |
| PH12015501096A1 (en) | Composition for immediate and extended release | |
| MX359288B (en) | Ivabradine hydrochloride form iv. | |
| MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| MX2015004362A (en) | Ketamine derivatives. | |
| MX357284B (en) | Quinone compounds for treating ape1 mediated diseases. | |
| MX2015005762A (en) | Co-micronisation product comprising ulipristal acetate. | |
| ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| AU2018256668A1 (en) | Combination therapy comprising an inhibitor of JAK, CDK and PIM | |
| WO2012002773A3 (en) | Phenylcarbamate compound and muscle relaxant containing the same | |
| IL225105A (en) | Heterocyclic compounds, process for their preparation, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments | |
| PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| MX2009007429A (en) | Pyridine compounds and their use as p2y12 antagonists. | |
| EP2871187A4 (en) | Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | |
| MX2014014579A (en) | O/w-emulsion-type topical pharmaceutical compositions containing a retinoid. |